Browsing Tag
Streeterville Capital
2 posts
SkinJect trial clearance gives Medicus Pharma a regulatory win as Nasdaq pressure builds
Medicus Pharma gains FDA clearance for its SkinJect Gorlin syndrome trial as stricter endpoints, secured debt and Nasdaq risks shape the outlook.
Can Beyond Air’s $32m lifeline drive profitability and global adoption of LungFit PH?
Find out how Beyond Air’s $32 million lifeline could drive profitability and global adoption of its LungFit PH nitric oxide therapy device.